Clinical Trial Update: Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcg [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating control of COPD symptoms in patients treated with tiotropium bromide 18 mcg once daily, ADOAIR 50/250 mcg twice daily, or both…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• ADOAIR (fluticasone propionate/salmeterol)
• Spiriva (tiotropium)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 4 | Status: COMPLETED | Results posted: 2016-11-10